KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Total Non-Current Liabilities data on record, last reported at $2.8 billion in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 15.5% year-over-year to $2.8 billion; the TTM value through Dec 2025 reached $2.8 billion, up 15.5%, while the annual FY2025 figure was $2.8 billion, 15.5% up from the prior year.
  • Total Non-Current Liabilities reached $2.8 billion in Q4 2025 per AMRX's latest filing, roughly flat from $2.8 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.9 billion in Q2 2021 and bottomed at $2.3 billion in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $2.7 billion, with a median of $2.8 billion recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: fell 12.44% in 2024, then increased 15.86% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $2.9 billion in 2021, then fell by 1.42% to $2.8 billion in 2022, then dropped by 9.62% to $2.6 billion in 2023, then decreased by 5.79% to $2.4 billion in 2024, then increased by 15.5% to $2.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $2.8 billion in Q4 2025, $2.8 billion in Q3 2025, and $2.4 billion in Q2 2025.